

CONTENTS

Contributors	xv
Foreword	xix
Preface	xxiii
 1 Glycochemistry: Overview and Progress	 1
<i>Matthew Schombs and Jacquelyn Gervay-Hague</i>	
1.1 Introduction, 1	
1.2 Nomenclature, Structures, and Properties of Sugars, 2	
1.2.1 Fischer Projection, 3	
1.2.2 Linear Forms of Monosaccharides, 4	
1.2.3 Cyclic Forms of Monosaccharides, 6	
1.2.4 Haworth and Mills Projections, 6	
1.2.5 Reeves Projection, 7	
1.2.6 Conformational Analysis, 7	
1.2.7 Disaccharides, Oligosaccharides, and Polysaccharides, 10	
1.2.8 Anomeric Effect, 11	
1.2.9 Mutarotation, 12	
1.3 Historical Overview of Carbohydrate Research, 12	
1.3.1 Emil Fischer (1852–1919): The Father of Carbohydrate Chemistry, 13	
1.3.2 Koenigs–Knorr Reaction, 15	
1.3.3 Karl Freudenberg (1886–1983), 16	
1.3.4 Burckhardt Helferich (1887–1982), 16	
1.3.5 Hermann Fischer (1888–1960), 17	

1.3.6	Claude Hudson (1881–1952), 17	
1.3.7	Horace Isbell (1898–1992), 18	
1.3.8	Melville Wolfrom (1900–1969), 18	
1.3.9	"Sugar" Raymond Lemieux (1920–2000), 19	
1.3.10	Ascent of De Novo Sugar Synthesis, 20	
1.4	Onward to the Twenty-First Century, 22	
1.4.1	Glycosyl Donors and Glycosylation Systems, 22	
1.4.2	Automated and One-Pot Methods for Oligosaccharide Synthesis, 24	
1.4.3	Solid-Phase Oligosaccharide Synthesis, 25	
1.4.4	Natural Product Synthesis, 25	
1.4.5	Carbohydrate-Based Therapeutics, 26	
1.5	Conclusion and Outlook, 28	
	References, 29	
2	Protecting Group Strategies in Carbohydrate Synthesis	35
	<i>Shang-Cheng Hung and Cheng-Chung Wang</i>	
2.1	Introduction, 35	
2.2	General Considerations for Protecting Group Selection, 36	
2.2.1	Retrosynthesis, 36	
2.2.2	Neighboring Group Participation, 37	
2.2.3	Inductive Effect, 38	
2.3	Common Protecting Groups in Carbohydrate Synthesis, 38	
2.3.1	Benzyl Ethers, 38	
2.3.2	Allyl Ethers, 40	
2.3.3	Silyl Ethers, 41	
2.3.4	Esters, 42	
2.3.5	Amine Protecting Groups, 43	
2.3.6	Diol Protection with Acetals and Ketals, 45	
2.4	Regioselective Protection of Monosaccharides, 46	
2.4.1	Through Differentiation of Primary Hydroxyls Using Bulky Protecting Groups, 47	
2.4.2	Through Protection of Diols with Acetals or Ketals, 50	
2.5	One-Pot Protection Methods, 57	
2.6	Conclusion, 61	
	References, 62	
3	General Aspects in O-Glycosidic Bond Formation	69
	<i>Xin-Shan Ye and Weigang Lu</i>	
3.1	Introduction, 69	
3.2	Some Basic Concepts, 69	
3.2.1	Mechanism of Glycosylation, 70	
3.2.2	Stereoselectivity, 70	
3.2.3	Anomeric Effect, 70	
3.2.4	Participation by Functional Groups in the Glycosyl Donor, 71	
3.2.5	The Armed–Disarmed Concept, 72	
3.2.6	Additives, 72	

3.2.7 Solvent Effect, 73	
3.2.8 Effects of Other Factors on Glycosylation, 73	
3.3 Methods for Glycosidic Bond Formation, 74	
3.3.1 Glycosyl Halides, 74	
3.3.2 Glycosyl Trichloroacetimidates, 76	
3.3.3 Thioglycosides, 78	
3.3.4 <i>n</i> -Pentenyl Glycosides, 80	
3.3.5 Carboxybenzyl Glycosides, 81	
3.3.6 Glycosyl Phosphates/Phosphites, 83	
3.3.7 Dehydrative Glycosylation, 84	
3.3.8 Glycals, 84	
3.3.9 Other Glycosylation Protocols, 86	
3.4 Glycosylation Strategies, 86	
3.4.1 One-Pot Glycosylation, 87	
3.4.2 Solid-Phase Oligosaccharide Synthesis, 88	
3.4.3 Chemoenzymatic Glycosylation, 90	
3.5 Conclusion, 91	
References, 91	
4 Controlling Anomeric Selectivity, Reactivity, and Regioselectivity in Glycosylations Using Protecting Groups	97
<i>Thomas Jan Boltje, Lin Liu, and Geert-Jan Boons</i>	
4.1 Introduction, 97	
4.2 Protecting Group and Control of Anomeric Selectivity of Glycosylations, 98	
4.2.1 Neighboring Group Participation of C2 Esters to Afford 1,2- <i>trans</i> -Glycosides, 98	
4.2.2 Remote Neighboring Group Participation, 99	
4.2.3 Neighboring Group Participation by Other Functional Groups, 100	
4.2.4 Neighboring Group Participation Using Chiral Auxiliaries to Obtain 1,2- <i>cis</i> -Glycosides, 103	
4.2.5 Intramolecular Aglycone Delivery, 106	
4.2.6 Anomeric Control by Electronic and Steric Effects, 108	
4.2.7 Conformational Selection Using a 3,5- <i>O</i> -Di- <i>tert</i> -Butylsilylidene Protecting Group, 112	
4.2.8 Stereoselective Introduction of 2-Deoxy-2-Aminoglycosides, 114	
4.3 Use of Protecting Groups for Chemoselective Glycosylations, 115	
4.4 Protecting Groups in Regioselective Glycosylations, 118	
4.5 Conclusion, 125	
References, 125	
5 Stereocontrolled Synthesis of Sialosides	131
<i>Chandrasekhar Navuluri and David Crich</i>	
5.1 Introduction, 131	
5.2 Conformational Analysis of Sialyl Oxocarbenium Ions, 132	
5.3 Additives in Sialylations, 133	

- 5.4 Leaving Groups in Sialylations, 134
- 5.5 Influence of the N5 Protecting Group on Reactivity and Selectivity, 134
- 5.6 4-*O*,5-*N*-Oxazolidinone Group and its Stereodirecting Influence on Sialylations, 139
- 5.7 4,5-*O*-Carbonate Protecting Group in α -Selective KDN Donors, 144
- 5.8 Other Cyclic and Bicyclic Protecting Systems for Sialyl Donors, 145
- 5.9 Mechanistic Aspects of Sialylation with Cyclically Protected Sialyl Donors, 146
- 5.10 Influence of Hydroxy Protecting Groups on Sialyl Donor Reactivity and Selectivity, 147
- 5.11 Stereoselective C-Sialoside Formation, 148
- 5.12 Stereoselective S-Sialoside Formation, 149
- 5.13 Conclusion, 151
- References, 151

6 Strategies for One-Pot Synthesis of Oligosaccharides 155

Bo Yang, Keisuke Yoshida, and Xuefei Huang

- 6.1 Introduction, 155
- 6.2 One-Pot Glycosylation from the Nonreducing End to the Reducing End, 156
 - 6.2.1 Reactivity-Based One-Pot Glycosylation: Fine-Tuning of Anomeric Reactivities, 156
 - 6.2.2 One-Pot Glycosylation Based on Chemoselective Activation of Different Types of Glycosyl Donors, 165
 - 6.2.3 Preactivation-Based Reactivity-Independent One-Pot Glycosylation, 170
- 6.3 Regioselective One-Pot Glycosylation: Construction of Oligosaccharides from the Reducing End to the Nonreducing End, 175
- 6.4 Hybrid One-Pot Glycosylation, 179
- 6.5 Conclusion, 183
- Acknowledgments, 183
- References, 183

7 Automated Oligosaccharide Synthesis: Techniques and Applications 189

Mattan Hurevich, Jeyakumar Kandasamy, and Peter H. Seeberger

- 7.1 Introduction, 189
- 7.2 Challenges and Limitations in Solution-Phase Oligosaccharide Synthesis, 190
- 7.3 Solid-Phase Oligosaccharide Synthesis, 191
 - 7.3.1 Strategies for Solid-Phase Oligosaccharide Synthesis, 192
- 7.4 Automated Oligosaccharide Synthesis, 193
 - 7.4.1 Technological Aspects of Automated Solid-Phase Oligosaccharide Synthesis, 193
 - 7.4.2 The First Decade of Automated Synthesis of Oligosaccharides, 194

7.4.3	Recent Improvements in Automated Oligosaccharide Synthesis,	197
7.4.4	Automated Synthesis of Conjugation-Ready Oligosaccharides,	197
7.4.5	HPLC-Assisted Automated Oligosaccharide Synthesis,	199
7.5	Microfluidic Techniques for Oligosaccharide Synthesis,	199
7.6	Conclusion and Outlook,	202
	Acknowledgments,	202
	References,	202
8	Sugar Synthesis by Microfluidic Techniques	205
	<i>Koichi Fukase, Katsunori Tanaka, Yukari Fujimoto, Atsushi Shimoyama, and Yoshiyuki Manabe</i>	
8.1	Introduction,	205
8.2	Microfluidic Glycosylation,	206
8.2.1	Microfluidic α -Sialylation,	206
8.2.2	Glycosylation with KDO,	212
8.2.3	Stereoselective β -Mannosylation under the Integrated Microfluidic and Batch Conditions,	214
8.2.4	Chemical N-Glycosylation of Asparagine under the Integrated Microfluidic and Batch Conditions,	215
8.3	Conclusion,	216
	References,	217
9	Chemoenzymatic Synthesis of Carbohydrates	221
	<i>Kasemsiri Chandarajoti and Jian Liu</i>	
9.1	Introduction,	221
9.2	Oligosaccharides and Polysaccharides Produced by GTases,	222
9.3	Chemoenzymatic Synthesis of HS,	223
9.3.1	Biosynthetic Pathway of HS and HS Biosynthetic Enzymes,	224
9.3.2	Application of Biosynthetic Enzymes in HS and Heparin Oligosaccharide Synthesis,	224
9.3.3	Strategy for Controlled Chemoenzymatic Synthesis,	228
9.4	Conclusion,	231
	References,	231
10	Synthesis of Glycosaminoglycans	235
	<i>Medel Manuel L. Zulueta, Shu-Yi Lin, Yu-Peng Hu, and Shang-Cheng Hung</i>	
10.1	Introduction,	235
10.2	General Strategies,	238
10.3	Synthesis of Derivatives of L-Idose and IdoA,	240
10.4	Synthesis via Stepwise Solution-Phase Assembly and Compound Diversification,	242
10.5	Synthesis via Solution-Phase One-Pot Assembly,	250
10.6	Polymer-Supported Synthesis and Automation,	253
10.7	GAG Mimetics,	256

10.8 Conclusion, 257	
References, 258	
11 Chemical Glycoprotein Synthesis	263
<i>Yasuhiro Kajihara, Masumi Murakami, and Carlo Unverzagt</i>	
11.1 Introduction, 263	
11.2 Oligosaccharide Structures, 264	
11.3 Biosynthesis of Glycoproteins, 265	
11.4 Chemical Protein Synthesis, 267	
11.4.1 Native Chemical Ligation, 267	
11.4.2 NCL without the aa-Cys Junction, 268	
11.5 Synthesis of Glycopeptides, 269	
11.6 Synthesis of Glycopeptide- α thioesters, 270	
11.6.1 Safety-Catch Linker, 271	
11.6.2 Thioesterification via Activation of C-Terminal Carboxylic Acids, 271	
11.6.3 Convergent Methods for the Synthesis of Glycopeptide- α Thioesters, 272	
11.6.4 Thioesterification via O $\rightarrow$ S Transesterification for the Synthesis of Glycopeptide- α Thioesters, 273	
11.6.5 Boc-SPPS for the Synthesis of Sialylglycopeptide- α Thioesters, 274	
11.7 Chemical Synthesis of Glycoproteins, 275	
11.7.1 Antibacterial Glycoprotein Diptericin Bearing Two O-Linked GalNAc Residues, 275	
11.7.2 Lymphotactin, 276	
11.7.3 Bacterial Immunity Protein Im7, 276	
11.7.4 MUC-2, 278	
11.7.5 GlyCAM-1, 279	
11.7.6 Monocyte Chemotactic Protein-3, 280	
11.7.7 Ribonuclease, 281	
11.7.8 Antifreeze Glycoproteins, 281	
11.7.9 Interleukin-8, 282	
11.7.10 Interferon- β -1a, 283	
11.7.11 Saposin C, 284	
11.7.12 Erythropoietin, 285	
11.8 Conclusion, 288	
References, 288	
12 Synthesis of Glycosphingolipids	293
<i>Suvarn S. Kulkarni</i>	
12.1 Introduction, 293	
12.2 Classification and Nomenclature of GSLs, 294	
12.3 Biological Significance of GSLs, 296	

12.4	Synthesis of GSLs, 297	
12.4.1	Synthesis of Globo- and Isoglobo-Series GSLs, 297	
12.4.2	Synthesis of Gangliosides, 310	
12.5	Conclusion, 320	
	References, 320	
13	Synthesis of Glycosylphosphatidylinositol Anchors	327
	<i>Charles Johnson and Zhongwu Guo</i>	
13.1	Introduction, 327	
13.2	Synthesis of the <i>Tryp. brucei</i> GPI Anchor, 328	
13.3	Synthesis of the Yeast GPI Anchor, 333	
13.4	Synthesis of the Rat Brain Thy-1 GPI Anchor, 335	
13.5	Synthesis of <i>Plasmodium falciparum</i> GPI Anchor, 340	
13.6	Synthesis of <i>Trypanosoma cruzi</i> GPI Anchor, 344	
13.7	Synthesis of a Human Sperm CD52 Antigen GPI Anchor, 349	
13.8	Synthesis of a Human Lymphocyte CD52 Antigen GPI Anchor, 351	
13.9	Synthesis of the Branched GPI Anchor of <i>Toxoplasma gondii</i> , 354	
13.10	Conclusion, 355	
	Acknowledgment, 356	
	References, 357	
14	Synthesis of Bacterial Cell Envelope Components	361
	<i>Akihiro Ishiwata and Yukishige Ito</i>	
14.1	Introduction, 361	
14.2	Peptidoglycan and Related Glycoconjugates, 362	
14.2.1	Lipid I, II, and IV Analogues, 362	
14.2.2	Peptidoglycan Fragments, 366	
14.3	LPS and Related Glycoconjugates, 371	
14.3.1	Lipid A, 371	
14.3.2	Oligo-KDO and Inner-Core Oligosaccharide, 373	
14.3.3	Outer-Core Polysaccharides, 376	
14.3.4	Capsular Polysaccharide, 377	
14.3.5	Secondary Cell-Wall Polysaccharide, 378	
14.3.6	Zwitterionic Polysaccharide, 378	
14.4	Lipoteichoic Acid, 380	
14.5	Mycolyl Arabinogalactan, LAM, and Related Glycoconjugates, 382	
14.5.1	Arabinan, Galactan, and Related Glycoconjugates, 382	
14.5.2	Mycolates and Related Glycoconjugates, 387	
14.5.3	LAM and Related Glycoconjugates, 388	
14.6	Oligosaccharides of Bacterial Glycoprotein and Related Glycoconjugates, 390	
14.6.1	O-Linked Oligosaccharide from <i>Bacillus</i> Collagen-Like Protein of Anthracis, 390	
14.6.2	N-Linked Glycans from the Gram-Negative Bacterium <i>C. jejuni</i> , 392	

14.7 Conclusion, 394

References, 395

15 Discoveries and Applications of Glycan Arrays

407

Chung-Yi Wu and Shih-Huang Chang

15.1 Introduction, 407

15.2 Discoveries of Glycan Arrays, 407

15.2.1 General, 407

15.2.2 Noncovalent Glycan Arrays, 408

15.2.3 Covalent Glycan Arrays, 409

15.2.4 Quality Control of Glycan Arrays, 411

15.2.5 Detection Methods of Glycan Arrays, 411

15.3 Applications of Glycan Array, 412

15.3.1 Enzyme Activity/Inhibition Studies, 412

15.3.2 Glycan Array for Diseases Detection and Vaccine Development, 413

15.3.3 Consortium for Functional Glycomics, 417

15.4 Conclusion, 418

References, 418

16 Synthesis and Applications of Glyconanoparticles, Glycodendrimers, and Glycoclusters in Biological Systems

425

Avijit Kumar Adak, Ching-Ching Yu, and Chun-Cheng Lin

16.1 Introduction, 425

16.2 Significance of Multivalent Binding Interactions in Biological Systems, 426

16.3 Glyconanoparticles, Glycodendrimers, and Glycoclusters: General Overview, 428

16.4 Plant Lectins, 431

16.4.1 Concanavalin A, 431

16.4.2 Peanut Agglutinin, 436

16.4.3 Wheat Germ Agglutinin, 437

16.4.4 *Ricinus communis* Agglutinin 120, 437

16.4.5 Other Plant Lectins, 438

16.5 AB₅ Toxins, 438

16.5.1 Cholera Toxin, 439

16.5.2 Shiga-Like Toxins, 439

16.6 Bacterial Adhesion Lectins, 440

16.6.1 FimH Adhesin, 441

16.6.2 PA-IL and PA-III, 442

16.7 Influenza Virus, 445

16.8 Detection of Bacteria, 445

16.9 Glyco-MNPs as Nanoprobes for Labeling Cells and Magnetic Resonance Imaging Agents, 446

16.10 Cyclopeptide-Based Glycoclusters as Vaccine Adjuvants, 447

16.11 Conclusion, 449	
Acknowledgments, 449	
References, 450	
17 Design and Synthesis of Carbohydrates and Carbohydrate Mimetics as Anti-Influenza Agents	455
<i>Mauro Pascolutti and Mark von Itzstein</i>	
17.1 Introduction, 455	
17.2 Influenza Viruses, 456	
17.2.1 Virus Morphology, 456	
17.2.2 Influenza A Virus Epidemiology, 457	
17.2.3 Influenza A Virus Life Cycle, 458	
17.3 Development of Anti-Influenza Therapeutics, 459	
17.4 Sialic Acid: The Viral Cell-Surface Receptor Ligand, 460	
17.5 Hemagglutinin, 460	
17.6 Sialidase, 461	
17.6.1 Influenza Virus Sialidase Active Site, 461	
17.6.2 Catalytic Mechanism of Influenza Virus Sialidase, 463	
17.7 Influenza Virus Sialidase as a Drug Discovery Target, 464	
17.7.1 Structure-Based Sialidase Inhibitor Design on a Sialic Acid Scaffold: Development of Zanamivir, 464	
17.7.2 Second-Generation Zanamivir, 466	
17.7.3 Sialidase Inhibitors Based on a Cyclohexene Scaffold: Development of Oseltamivir, 468	
17.7.4 Sialidase Inhibitors Based on Five-Membered Ring Scaffolds, 470	
17.7.5 Sialidase Inhibitors Based on an Aromatic Ring Scaffold, 471	
17.8 Structural Differences Recently Identified in Influenza A Virus Sialidase Subtypes, 471	
17.9 New Influenza Virus Sialidase Inhibitors Targeting the 150-Cavity, 473	
References, 476	
18 Design and Synthesis of Ligands and Antagonists of Siglecs as Immune Response Modifiers	483
<i>Hajjaj H. M. Abdu-Allah, Hideharu Ishida, and Makoto Kiso</i>	
18.1 Introduction, 483	
18.2 Lectins, 484	
18.3 Siglecs, 484	
18.3.1 Ligands for Siglecs, 486	
18.3.2 Structural Features for Siglec Recognition, 487	
18.3.3 Sialic Acid Substructural Specificities for Siglecs, 487	
18.4 Siglecs and Innate Immunity, 489	
18.4.1 Pathogen Internalization by Innate Immune Cells: Phagocytosis and Endocytosis by Siglecs, 490	

- 18.4.2 Attenuation of Inflammatory Responses, 491
- 18.4.3 Immune Evasion by Pathogens via Siglec Ligation, 491
- 18.4.4 Regulation of the Life Span of Myeloid Cells in the Context of Inflammation by Siglec-8, Siglec-9, and Siglec-F, 492
- 18.4.5 Regulation of NK Cell Function by Siglec-7, 492
- 18.4.6 Direct Role for Siglecs in T Cells, 493
- 18.4.7 Siglecs in B-Cell Biology and Maintenance of Immunological Tolerance, 493
- 18.5 Design and Synthesis of High-Affinity Ligands for Siglecs, 494
 - 18.5.1 Sialoadhesin, 494
 - 18.5.2 CD22, 495
- 18.6 Conclusion and Future Directions, 501
- References, 502

19 Sugar-Protein Hybrids for Biomedical Applications

509

Macarena Sánchez-Navarro and Benjamin G. Davis

- 19.1 Introduction, 509
- 19.2 Challenges in the Development of Glycoprotein-Based Therapeutics, 510
- 19.3 Why Unnatural? 510
- 19.4 Retrosynthetic Analysis, 511
- 19.5 Linkages, 512
 - 19.5.1 Thioether, 512
 - 19.5.2 Disulfides, 514
 - 19.5.3 Amide, 514
 - 19.5.4 Amine, 515
 - 19.5.5 Amidine, 516
 - 19.5.6 Urea and Thiourea, 516
 - 19.5.7 Diazonium, 517
 - 19.5.8 Triazole, 517
 - 19.5.9 Oxime, 518
 - 19.5.10 CC Bond Formation, 519
 - 19.5.11 Enzymatic Extension, 520
- 19.6 Glycoprotein-Based Therapeutics, 521
 - 19.6.1 Carbohydrate-Protein-Based (Glycoconjugate) Vaccines, 521
 - 19.6.2 Synthetic Glycoproteins as Pathogen-Process Inhibitors, 522
 - 19.6.3 Targeted Delivery, 524
 - 19.6.4 Enzyme-Replacement Therapy, 525
 - 19.6.5 Synthetic Glycoproteins as *In Vivo* Reporters of Disease, 526
- 19.7 Conclusion, 527
- References, 527